Abstract
I have been invited to comment on the recent debate in theJournal of Thrombosis and Haemostasisabout the need for laboratory monitoring of low‐molecular‐weight heparin (LMWH) therapy [1,2]. Bounameux and De Moerloose summarized the rationale for laboratory monitoring of LMWH therapy, identified limitations of laboratory assays that are used for that purpose, and concluded that available evidence does not support laboratory monitoring of LMWH [2]. They acknowledge that treatment with fixed‐dose weight‐based LMWH may not be suitable in certain situations such as pregnancy, very light or heavy individuals, in newborns and in those with renal impairment, and they concede that dose adjustment in response to laboratory monitoring of heparin activity may be indicated in these relatively uncommon circumstances.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
